Take 5 minutes to catch up on NeurologyLive's highlights from the week ending November 27, 2020.
Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
Pascal Sati, PhD, explores how advanced imaging technology is on a collision course with artificial intelligence in what is shaping up to be a revolutionary period for the diagnosis and management of MS.
Michael Okun, MD, executive director of the Norman Fixel Institute for Neurological Diseases sat down to discuss his viewpoint paper on changing the approval system for neurotechnological devices in rare diseases.
In this episode, the panel of Fred Lublin, MD; Patricia K. Coyle, MD; Scott Newsome, DO, MSCS, FAAN; and Mark Freedman, MD, discuss their clinical work-up criteria, including the use of cerebral spinal fluid, to make a more accurate multiple sclerosis diagnosis.
The vascular neurologist at Memorial Hermann Medical Group explained how clinical stroke care will change in 2021 amid the COVID-19 pandemic, including the importance of MCUs and how telemedicine and televisits will help patients adhere to a more rigid treatment regimen.
Madison Hansen, of the Department of Neurology and Neurotherapeutics, and the Neuroinnovation and Multiple Sclerosis and Neuroimmunology Imaging Programs, UT Southwestern Medical Center, discussed effectively navigating the nuances of this unique patient population will ultimately help drive innovative solutions for this generation and those to come.